GO FOR FIRST-LINE VYZULTA IN A RANGE OF PATIENT TYPES

Choose monotherapy with VYZULTA in appropriate patients who:

Need a powerful first-line IOP-lowering treatment when beginning their glaucoma journey^1-4

Are not adequately responding to their current PGA treatment, including latanoprost 0.005%^1,2

Received a prior diagnosis of ocular hypertension and may be at risk of developing open-angle glaucoma^1,5

Have inadequately controlled IOP following SLT^6,7*

Provide powerful IOP reduction and excellent tolerability with VYZULTA to appropriate patients in your practice, including patients with both high and low baseline IOP.^1-3,8

IOP CONTROL IN THE REAL WORLD

Real-world study: treatment-naïve patients

First-line use of VYZULTA is supported by data from a real-world, multicenter retrospective chart review of treatment-naïve patients with open-angle glaucoma or ocular hypertension.⁸

DOWNLOAD ARTICLE

IOP control in the real world heading with article image, article synopsis, and downward-facing arrow link to article on switch patients

Real-world study: switch patients

Switching to VYZULTA is supported by data from a real-world, multicenter retrospective chart review of patients with open-angle glaucoma or ocular hypertension receiving 1 or 2 IOP-lowering therapies who were switched to VYZULTA.⁹

DOWNLOAD ARTICLE

Next | Establishing Treatment Goals

*In clinical trials, patients with a history of SLT in either eye >90 days prior to study entry could be enrolled.^6,7

PGA=prostaglandin analog; SLT=selective laser trabeculoplasty.

Sign up

Sign up to receive updates and learn more about VYZULTA.

image of VYZULTA® bottle and packaging

All fields are required. You consent to receive communications containing information and educational resources about VYZULTA, as well as other communications from Bausch + Lomb. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Legal Notice.

INDICATION

VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here to see full Prescribing Information.

INDICATION

VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent

References: 1. VYZULTA. Prescribing Information. Bausch & Lomb Inc. 2. Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL; VOYAGER Study Group. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open-angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738-745. 3. Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018;27(1):7-15. 4. Okeke CO, Burstein ES, Trubnik V, et al. Retrospective chart review on real-world use of latanoprostene bunod 0.024% in treatment-naïve patients with open-angle glaucoma. Ophthalmol Ther. 2020;9(4):1041-1053. 5. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714-720, 829-830. 6. APOLLO. ClinicalTrials.gov identifier: NCT01749904. Updated November 7, 2018. Accessed March 18, 2024. 7. LUNAR. ClinicalTrials.gov identifier: NCT01749930. Updated November 21, 2018. Accessed March 15, 2024. 8. Kawase K, Vittitow JL, Weinreb RN, Araie M; JUPITER Study Group. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612-1627. 9. Okeke CO, Cothran NL, Brinkley DA, Rahmatnejad K, Rodiño FJ, Deom JE. Latanoprostene bunod 0.024% in patients with open-angle glaucoma switched from prior pharmacotherapy: a retrospective chart review. Clin Ophthalmol. 2024;18:409-422.